| Literature DB >> 25941137 |
Masao Omata1,2, Tatsuo Kanda3, Osamu Yokosuka4, Darrell Crawford5, Mamun Al-Mahtab6, Lai Wei7, Alaaeldin Ibrahim8, George K K Lau9, Barjesh C Sharma10, Saeed S Hamid11, Wan-Long Chuang12, A Kadir Dokmeci13.
Abstract
Estimated hepatitis C virus (HCV) infection rates in the general populations were 1.3, 0.9, 0.4-1.0, 14.7, 0.1-0.3, 0.9-1.9, 1.0-2.0, 5, 4.4-8.6 and 0.5-1.3 % in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. The main HCV genotypes (Gs) are G1, G3, G1b, G4, G1b, G3, G1b, G3, G1b and G2, and G1 in Australia, Bangladesh, Mainland China, Egypt, Hong Kong, India, Japan, Pakistan, Taiwan and Turkey, respectively. Of IL28B genotypes, favorable alleles are ~50 % in Australia and Turkey, but 60-70 % in most of the other Asian countries. Peginterferon plus ribavirin is available in all ten Asian Pasific countries. In addition, HCV NS3/4A protease inhibitors with peginterferon plus ribavirin are currently available in several countries. Clinical trials of interferon-free regimens for HCV are ongoing in most of the ten Asian Pacific countries.Entities:
Keywords: Asian Pacific countries; Direct-acting antivirals; HCV; IL28B
Mesh：
Substances：
Year: 2015 PMID： 25941137 DOI： 10.1007/s12072-015-9630-4
Source DB: PubMed Journal: Hepatol Int ISSN： 1936-0533 Impact factor: 9.029